[{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2025-02-25T13:39:05.076Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"f6ffbda8-da78-4ee6-a86e-42e6291f385e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00083512","created_at":"2021-01-18T00:14:16.293Z","updated_at":"2025-02-25T14:39:12.760Z","phase":"","brief_title":"Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme","source_id_and_acronym":"NCT00083512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/22/2004","start_date":" 06/22/2004","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-14"},{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"da630ed2-aba8-4d08-84f9-a31e25b0efa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06527495","created_at":"2025-02-27T07:56:52.092Z","updated_at":"2025-02-27T07:56:52.092Z","phase":"Phase 1/2","brief_title":"Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT06527495","lead_sponsor":"Assiut University","biomarkers":" KDR • VEGFA","pipe":"","alterations":" ","tags":["KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-07-30"},{"id":"0666a404-eaf5-4d66-b6d1-3dc8a91ce03c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06430372","created_at":"2024-06-01T04:22:51.567Z","updated_at":"2024-07-02T16:35:00.735Z","phase":"Phase 1","brief_title":"Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract","source_id_and_acronym":"NCT06430372","lead_sponsor":"Institute of Automation, Chinese Academy of Sciences","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-05-27"},{"id":"d4e71f27-baf6-4d04-a5d9-04763d342227","acronym":"NCI-2018-02831","url":"https://clinicaltrials.gov/study/NCT03779867","created_at":"2021-01-18T18:41:45.990Z","updated_at":"2024-07-02T16:35:06.053Z","phase":"","brief_title":"Acute Exercise Intervention in Breast Cancer Survivors","source_id_and_acronym":"NCT03779867 - NCI-2018-02831","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"189af0e0-df53-44e2-bea1-ee75b0bbd519","acronym":"KIWIS","url":"https://clinicaltrials.gov/study/NCT03996096","created_at":"2021-01-18T19:38:46.410Z","updated_at":"2024-07-02T16:35:19.368Z","phase":"","brief_title":"Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.","source_id_and_acronym":"NCT03996096 - KIWIS","lead_sponsor":"University Hospital, Caen","biomarkers":" VEGFA • IFNG • IL6 • TNFA • IL2 • IL10 • TGFB1 • TNFRSF11B","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • IL2 • IL10 • TGFB1 • TNFRSF11B"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/23/2019","start_date":" 04/23/2019","primary_txt":" Primary completion: 03/16/2023","primary_completion_date":" 03/16/2023","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2024-02-14"},{"id":"2bb68c69-6dfa-4aab-b5ea-dc75b65d4dea","acronym":"NuTide:301","url":"https://clinicaltrials.gov/study/NCT02723240","created_at":"2021-04-20T20:52:51.136Z","updated_at":"2024-07-02T16:35:19.505Z","phase":"Phase 1","brief_title":"NUC-3373 in Advanced Solid Tumours","source_id_and_acronym":"NCT02723240 - NuTide:301","lead_sponsor":"University of Oxford","biomarkers":" KRAS • BRAF • VEGFA","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • BRAF • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fosifloxuridine nafalbenamide (NUC-3373)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 02/24/2020","primary_completion_date":" 02/24/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2024-02-14"},{"id":"e86d670d-ff10-4e93-b7c9-1b7a0035cc36","acronym":"","url":"https://clinicaltrials.gov/study/NCT06230965","created_at":"2024-01-30T20:21:16.537Z","updated_at":"2024-07-02T16:35:21.824Z","phase":"","brief_title":"Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment","source_id_and_acronym":"NCT06230965","lead_sponsor":"Affiliated Hospital of Nantong University","biomarkers":" VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9","pipe":"","alterations":" ","tags":["VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-30"},{"id":"9687712d-99d6-4383-b6f4-ea8c602d3944","acronym":"CAT_PB","url":"https://clinicaltrials.gov/study/NCT06065592","created_at":"2023-10-04T16:11:23.801Z","updated_at":"2024-07-02T16:35:34.331Z","phase":"Phase 1","brief_title":"Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms","source_id_and_acronym":"NCT06065592 - CAT_PB","lead_sponsor":"Lebanese University","biomarkers":" PD-1 • VEGFA • CDKN2B • TNFA • CTLA4","pipe":" | ","alterations":" CTLA4 expression","tags":["PD-1 • VEGFA • CDKN2B • TNFA • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-06"},{"id":"ef958c21-2bd2-4580-9476-499c60150559","acronym":"VICKI","url":"https://clinicaltrials.gov/study/NCT06020651","created_at":"2023-08-31T13:09:53.820Z","updated_at":"2024-07-02T16:35:38.540Z","phase":"","brief_title":"Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside","source_id_and_acronym":"NCT06020651 - VICKI","lead_sponsor":"Institut Mutualiste Montsouris","biomarkers":" VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B","pipe":"","alterations":" ","tags":["VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-31"},{"id":"71aeb5fd-d9ae-483d-9a0d-2d87cddeca9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05484687","created_at":"2022-08-02T12:55:58.509Z","updated_at":"2024-07-02T16:35:41.261Z","phase":"","brief_title":"Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors","source_id_and_acronym":"NCT05484687","lead_sponsor":"Affiliated Hospital of Nantong University","biomarkers":" VEGFA • IL6","pipe":"","alterations":" ","tags":["VEGFA • IL6"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2023-08-02"},{"id":"f7825010-4c0f-4823-a337-62c43de4d013","acronym":"","url":"https://clinicaltrials.gov/study/NCT04755452","created_at":"2021-02-16T12:53:41.346Z","updated_at":"2024-07-02T16:35:45.259Z","phase":"","brief_title":"The Effect of Pneumoperitoneum (Raised Pressure in the Peritoneal Cavity) During Robotic Kidney/Prostate Cancer Surgery.","source_id_and_acronym":"NCT04755452","lead_sponsor":"Aalborg University Hospital","biomarkers":" VEGFA • KIM1 • CALB1 • CLU • LCN2","pipe":"","alterations":" ","tags":["VEGFA • KIM1 • CALB1 • CLU • LCN2"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/23/2020","start_date":" 12/23/2020","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2023-06-22"},{"id":"0c027e78-6ae5-4f16-b649-8a086aef24f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02609880","created_at":"2021-01-18T12:40:44.469Z","updated_at":"2024-07-02T16:35:45.523Z","phase":"","brief_title":"Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer","source_id_and_acronym":"NCT02609880","lead_sponsor":"University of Florida","biomarkers":" VEGFA • IL6 • TNFA • CXCL8","pipe":"","alterations":" ","tags":["VEGFA • IL6 • TNFA • CXCL8"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 04/18/2019","primary_completion_date":" 04/18/2019","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-06-15"},{"id":"30c12ff9-e4f6-4aaa-b23a-ab2e125bc519","acronym":"","url":"https://clinicaltrials.gov/study/NCT03392584","created_at":"2021-11-18T23:54:56.929Z","updated_at":"2024-07-02T16:35:51.638Z","phase":"","brief_title":"Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters","source_id_and_acronym":"NCT03392584","lead_sponsor":"Oslo University Hospital","biomarkers":" VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A","pipe":"","alterations":" ","tags":["VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 01/08/2022","study_completion_date":" 01/08/2022","last_update_posted":"2023-04-03"},{"id":"14691476-262f-4a49-a891-fa28962412ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02219711","created_at":"2021-01-17T17:38:13.217Z","updated_at":"2024-07-02T16:35:54.001Z","phase":"Phase 1","brief_title":"Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02219711","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 193","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2022","study_completion_date":" 04/27/2022","last_update_posted":"2023-03-06"},{"id":"4fd712ea-8160-4d7f-a9af-a619b6bd209f","acronym":"SLURP","url":"https://clinicaltrials.gov/study/NCT05745857","created_at":"2023-02-27T15:01:10.509Z","updated_at":"2024-07-02T16:35:54.699Z","phase":"Phase 2","brief_title":"Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas","source_id_and_acronym":"NCT05745857 - SLURP","lead_sponsor":"University Medical Center Groningen","biomarkers":" EGFR • VEGFA","pipe":"","alterations":" ","tags":["EGFR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-02-27"},{"id":"e6a4679a-3426-425a-a0da-b8e775fb9844","acronym":"","url":"https://clinicaltrials.gov/study/NCT05682924","created_at":"2023-01-12T15:02:34.059Z","updated_at":"2024-07-02T16:35:57.708Z","phase":"","brief_title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","source_id_and_acronym":"NCT05682924","lead_sponsor":"Samara State Medical University","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2023-01-12"},{"id":"67668528-5408-4edc-9d86-1a1632971ecf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777943","created_at":"2021-01-18T18:41:15.452Z","updated_at":"2024-07-02T16:35:59.268Z","phase":"","brief_title":"Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis","source_id_and_acronym":"NCT03777943","lead_sponsor":"University Ghent","biomarkers":" VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1","pipe":"","alterations":" ","tags":["VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 03/28/2022","primary_completion_date":" 03/28/2022","study_txt":" Completion: 03/28/2022","study_completion_date":" 03/28/2022","last_update_posted":"2022-12-12"},{"id":"4a644411-a00e-4214-bf86-6017965e452b","acronym":"FACT","url":"https://clinicaltrials.gov/study/NCT05546047","created_at":"2022-09-19T13:55:48.736Z","updated_at":"2024-07-02T16:36:01.576Z","phase":"Phase 4","brief_title":"A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients","source_id_and_acronym":"NCT05546047 - FACT","lead_sponsor":"NephroNet, Inc.","biomarkers":" VEGFA • TGFB1 • PODXL","pipe":"","alterations":" ","tags":["VEGFA • TGFB1 • PODXL"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 03/14/2019","start_date":" 03/14/2019","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2024","study_completion_date":" 10/27/2024","last_update_posted":"2022-10-31"},{"id":"8e3d63ad-09a8-4b3b-b349-bd66776114b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00560495","created_at":"2021-01-18T02:02:33.191Z","updated_at":"2024-07-02T16:36:03.071Z","phase":"Phase 1","brief_title":"Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00560495","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" VEGFA • IL6 • CXCL8 • TGFB1","pipe":"","alterations":" ","tags":["VEGFA • IL6 • CXCL8 • TGFB1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2007","start_date":" 05/01/2007","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 07/01/2008","study_completion_date":" 07/01/2008","last_update_posted":"2022-10-03"},{"id":"6b88056b-740c-4793-8c44-c7eb87101b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01555268","created_at":"2021-01-18T06:35:03.601Z","updated_at":"2024-07-02T16:36:04.006Z","phase":"Phase 1","brief_title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01555268","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" VEGFA • CD34","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2011","start_date":" 10/31/2011","primary_txt":" Primary completion: 09/24/2013","primary_completion_date":" 09/24/2013","study_txt":" Completion: 08/03/2016","study_completion_date":" 08/03/2016","last_update_posted":"2022-09-13"}]